BofA raised the firm’s price target on Waystar (WAY) to $43 from $36 and keeps a Buy rating on the shares. The firm applies a premium valuation to the profitable health IT peer group average as a function of Waystar’s above-average revenue growth in the high single digits to low double digits and 40% EBITDA margins, the analyst tells investors in a 2025 outlook note for the Healthcare Tech and Distribution group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAY:
- Waystar price target raised to $42 from $36 at Barclays
- Waystar price target raised to $42 from $36 at Canaccord
- Waystar increases revolving credit facility borrowing capacity to $400M
- Waystar upgraded to Strong Buy from Outperform at Raymond James
- Waystar price target raised to $34 from $31 at Deutsche Bank